Dr Reddy's recalls its drug in the US

The company recalls Rivastigmine Tartrate, used for the treatment of mild to moderate dementia of the Alzheimer's type or Parkinson's disease


It has been classified as a class-II recall

Dr Reddy's Laboratories (DRL) is recalling Rivastigmine Tartrate Capsules of 1.5 mg strength from the USA market, due to 'Failed Dissolution Specifications'.

A total of 60 bottles of 2952 units are recalled on the direction of US Food and Drug Administration (US FDA). The batch was manufactured at DRL's Bachupally unit.

It has been classified as a class-II recall which FDA defined as "a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."



Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email